Kelyniam Global Inc. has announced the renewal of its licensing agreement with Finceramica Faenza S.p.A., an Italian biomaterials company. The three-year extension grants Kelyniam expanded access to Finceramica's product portfolio, including SINTlife, a fully resorbable synthetic graft, and Surgery V-Connect, a Smart Augmented Reality System. The agreement is expected to strengthen Kelyniam's position in the U.S. market and enable entry into new markets in bone regeneration and orthopedic applications. SINTlife is anticipated to receive FDA clearance within two years.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kelyniam Global Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571091-en) on November 07, 2025, and is solely responsible for the information contained therein.